Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s latest stock calls as he shared how to navigate Wednesday’s tough tape. Cramer believes that the stock should have gone higher, as he stated: What can you do on days like today? Well, the investing club… We like to buy, not big, but we’re not sellers. Why? Couple of reasons. We now think that Iran’s response could be more anemic than its previous barrage of pain. We’re going to find out soon enough though. We also like the stock market… when it’s oversol ...

Market Overview - The overall market is facing consistent pressure, primarily due to higher-than-expected inflation data and adjustments in the labor market [2][3] - The short end of the yield curve has seen significant increases, particularly the 2-year yield, indicating a shift in market sentiment regarding Federal Reserve actions [2][3] - Geopolitical tensions, especially in the Middle East, are contributing to market uncertainty, particularly affecting energy and shipping sectors [3] Oracle - Oracle's stock has seen a significant pullback of approximately 21% year-to-date and a 55% decline from its recent highs following earnings reports [5][6] - There is a belief that Oracle may have temporarily bottomed, with support levels around $155 to $160, suggesting potential for upside if market stability is achieved [7][8] - Technical analysis indicates a bearish trend, with caution advised despite signs of a possible short-term bottom [10][12] Johnson & Johnson - Johnson & Johnson has performed relatively well, up about 14% this year, despite a 6% pullback from recent highs [19][20] - The stock is viewed as defensive, with a potential for building off current levels, and a risk reversal strategy is suggested to capture further upside [18][19] - Technical indicators show a constructive chart, but there are concerns about weakening price momentum and potential breakdowns below key support levels [22][24] Starbucks - Starbucks has been the strongest performer this year, but there are mixed opinions regarding its costly turnaround strategy [25][27] - The stock is currently positioned for potential downside, with a strategy to buy puts to capture further weakness while having the opportunity to acquire shares at lower levels [28][31] - Technical analysis indicates defined resistance around $100 to $104 and support near $80, with recent trading behavior resembling that of a utility stock rather than a growth company [33][34]

Core Viewpoint - Glencore's South African ferrochrome unit is considering withdrawing from negotiations with the government regarding a discounted electricity package due to perceived unfavorable conditions [1] Group 1: Company Insights - The executive from Glencore indicated that the current terms of the electricity package are not satisfactory for the company [1] - The potential withdrawal from talks highlights the challenges faced by the ferrochrome unit in securing favorable operational conditions [1] Group 2: Industry Context - The situation reflects broader issues within the South African energy sector, where companies are seeking more favorable terms to ensure competitiveness [1] - The outcome of these negotiations could have significant implications for the ferrochrome industry in South Africa, particularly in terms of operational costs and profitability [1]

Key Takeaways AbbVie shares dropped 5.2% as J&J secured FDA approval for Icotyde in plaque psoriasis.Skyrizi, AbbVie's top drug, posted $17.6B sales in 2025 and is key to post-Humira growth.Icotyde's oral delivery and expanding indications may intensify IL-23 competition over time.Shares of AbbVie (ABBV) fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as investors grow wary of Johnson & Johnson’s (JNJ) newly approved immunology therapy, Icotyde, which could emerg ...

According to the now well publicized MIT-affiliated research and reporting, fewer than 5% of enterprise AI pilots ever deliver measurable business value. The other 95%? They’re still stuck in what we call AI Purgatory: exciting demos, scattered pilots, and vanishing trust.For the past couple of years, corporate leaders have been sprinting into the AI era with a mixture of urgency and anxiety. Boards are calling. Investors are asking. Competitors are announcing. And CIOs, under immense pressure, have respond ...

Core Viewpoint - Johnson & Johnson (J&J) has transitioned by spinning off its consumer health business to focus on innovative medicine and medtech, despite facing challenges from the loss of exclusivity of its top-selling drug, Stelara [1][2] Group 1: Company Performance - J&J has shown resilience by managing growth in its two main businesses despite the decline of Stelara [2] - The company's shares have increased by 15% this year, contrasting with the S&P 500's decline, indicating strong performance during uncertain market conditions [4] - J&J has 28 platforms or products generating at least $1 billion annually, allowing it to move past the Stelara exclusivity loss [5] Group 2: Financial Metrics - J&J's market capitalization is $572 billion, with a current share price range between $235.50 and $239.11 [6] - The company has a gross margin of 67.97% and a dividend yield of 2.19% [6] Group 3: Dividend Growth - J&J is recognized as a Dividend King, having increased its dividend for over 50 years, demonstrating a commitment to shareholder returns [7] - The company pays a dividend of $5.20, which is higher than the S&P 500's dividend yield of 1.1%, making it an attractive option for passive income [9]

Core Viewpoint - Current cheaper valuations in the market present a buying opportunity for investors in ASX shares, suggesting a focus on long-term investment rather than panic selling [1] Group 1: Lovisa Holdings Ltd (ASX: LOV) - Lovisa has established a significant global presence with over 1,100 stores across various regions including Asia, Europe, Africa, and the Americas [2][3] - The company reported a 22.7% increase in core revenue to $498.1 million and a 21.5% rise in net profit after tax (NPAT) to $69.6 million for the HY26 period, alongside a comparable store sales growth of 2.2% [3] - Ongoing expansion is expected to enhance revenue and margins, positioning Lovisa as a leading investment choice for the upcoming decade [4] Group 2: Betashares Global Quality Leaders ETF (ASX: QLTY) - The QLTY ETF offers diversification benefits, making it a suitable investment during market volatility, particularly in high-quality businesses that can withstand economic uncertainty [5] - The ETF invests in a global portfolio of 150 businesses with strong financial metrics, including high return on equity (ROE), low leverage, and stable earnings [6] - Since its inception in November 2018, the QLTY ETF has achieved an average return of 13.5% up to February 2026, indicating strong long-term performance potential [7]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the potential of AI to unlock multi-trillion-dollar opportunities, reinforcing the optimistic outlook on AI's economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is seen as a catalyst for redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, suggesting that it could be a significant investment opportunity [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8]

Core Viewpoint - Johnson & Johnson's new oral psoriasis medication, Icotyde, has received FDA approval, positioning it as a competitive alternative to existing injectable treatments in the market [1][2]. Group 1: Product Overview - Icotyde is the first oral treatment approved for moderate to severe plaque psoriasis, an autoimmune condition characterized by rough skin patches [1]. - The drug targets the IL-23 receptor, similar to popular injectable treatments like Tremfya and Skyrizi, providing patients with an oral option [2]. Group 2: Market Potential - Johnson & Johnson anticipates that Icotyde could become the first-line systemic treatment for psoriasis, bridging the gap between topical treatments and injections [2]. - The company estimates that peak annual sales for Icotyde could exceed $5 billion once it is approved for additional autoimmune conditions, including psoriatic arthritis, ulcerative colitis, and Crohn's disease [5]. Group 3: Patient Demographics and Appeal - Approximately 8 million people in the U.S. suffer from plaque psoriasis, with 75% of patients not progressing to injections due to needle aversion [3]. - The company believes that Icotyde's simple once-daily oral dosage will be appealing to patients who are hesitant to use injectable treatments [4]. Group 4: Competitive Landscape - The approval of Icotyde comes as the psoriasis treatment market becomes increasingly competitive, with drugmakers developing advanced therapies beyond standard topical treatments [2]. - Rival injectable treatments, such as Tremfya and Skyrizi, are priced around $100,000 annually, highlighting the potential market disruption Icotyde could cause [4].

The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, the company said on Wednesday, paving the way for a more convenient treatment option for patients with... ...